Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders succeed in the markets with accurate stock market intelligence.
ENOV
$26.59+Infinity%1D
Analyst Views on ENOV
Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 49.00 USD with a low forecast of 44.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 49.00 USD with a low forecast of 44.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.470
Low
44.00
Averages
49.00
High
58.00
Current: 26.470
Low
44.00
Averages
49.00
High
58.00
Baird
Outperform -> Outperform
downgrade
$50 -> $45
2025-11-07
Reason
Baird
Price Target
$50 -> $45
2025-11-07
downgrade
Outperform -> Outperform
Reason
Baird lowered the firm's price target on Enovis to $45 from $50 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results with consistency improved moving into 2026.
Canaccord
Buy
downgrade
$70 -> $58
2025-08-08
Reason
Canaccord
Price Target
$70 -> $58
2025-08-08
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Enovis to $58 from $70 and keeps a Buy rating on the shares. The firm said they posted a solid Q2 beat and noted the company maintained expectations to be FCF positive for the FY25 while CEO Damien McDonald outlined a vision focused on margin expansion, cash flow improvement, and disciplined execution through the EGX operating system.
UBS
Buy
downgrade
$65 -> $57
2025-08-08
Reason
UBS
Price Target
$65 -> $57
2025-08-08
downgrade
Buy
Reason
UBS lowered the firm's price target on Enovis to $57 from $65 and keeps a Buy rating on the shares.
Jehoshaphat Research
Strong Sell
initiated
2025-07-17
Reason
Jehoshaphat Research
Price Target
2025-07-17
initiated
Strong Sell
Reason
Jehoshaphat Research announced a new short position in Enovis. In a note to investors, the firm says it believes Enovis shareholders own a growth story "that's largely a figment of accountants' imaginations." The firm is short this stock because "we think its key numbers are largely fake, its real earnings power is far lower, and because it has gotten by for many years on a plethora of accounting and language games that simply won't work if the company is too debt-laden to do more large, frequent deals."
Reference Link
About ENOV
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
